Apr 30, 2025
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Oct 27, 2020
REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
Aug 13, 2020
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
May 27, 2020
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
May 14, 2020
Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta(TM) for metastatic non-small cell lung cancer with METex14
Apr 22, 2020
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Apr 21, 2020
Italian Respiratory Devices Industry Assessment 2020 with Bayer, ResMed, Chiesi Farmaceutici, GlaxoSmithKline, Novartis, and Boehringer Ingelheim Dominating
Mar 28, 2020
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Mar 18, 2020
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Mar 18, 2020
Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Mar 03, 2020
Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease
Dec 11, 2019
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Nov 17, 2019
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Nov 15, 2019
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Oct 23, 2019
Women living with metastatic breast cancer in British Columbia now have public access to KISQALI®
Oct 08, 2019
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Oct 02, 2019
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum